|
Showing 1 - 5 of
5 matches in All Departments
Since the publication of the first edition, there have been
advances in both the diagnosis and the management of many of the
cholestatic liver diseases. Cholestatic Liver Disease, Second
Edition thoroughly updates the topics previously addressed, such as
primary biliary cirrhosis, primary sclerosing cholangitis and
cholestatic variants of drug hepatotoxicity and viral disease. New
treatments, such as the development of the farnesoid X receptor
agonists for the treatment of PBC, are highlighted. Current
guidelines and areas of uncertainty are also covered. Additionally,
new chapters have been added to reflect the changing landscape of
cholestatic liver disease. Cholestatic Liver Disease, Second
Edition is a concise yet comprehensive summary of the current
status of the field and is of value to clinicians and researchers
interested in patients with cholestatic liver disease provide that
will help to guide patient management and stimulate investigative
efforts.
Since the publication of the first edition, there have been
advances in both the diagnosis and the management of many of the
cholestatic liver diseases. Cholestatic Liver Disease, Second
Edition thoroughly updates the topics previously addressed, such as
primary biliary cirrhosis, primary sclerosing cholangitis, and
cholestatic variants of drug hepatotoxicity and viral disease. New
treatments, such as the development of the farnesoid X receptor
agonists for the treatment of PBC, are highlighted. Current
guidelines and areas of uncertainty are also covered. Additionally,
new chapters have been added to reflect the changing landscape of
cholestatic liver disease. Cholestatic Liver Disease, Second
Edition is a concise yet comprehensive summary of the current
status of the field and is of value to clinicians and researchers
interested in patients with cholestatic liver disease provide that
will help to guide patient management and stimulate investigative
efforts.
Get the authoritative, up-to-date information you need on liver
disease from the 7th Edition of the most trusted reference
worldwide. Covering both basic science and recent clinical
developments, this revised edition by Drs. Arun J. Sanyal, Thomas
D. Boyer, Norah A. Terrault, and Keith D. Lindor, provides an
in-depth, comprehensive look at the pathophysiology, diagnostic,
and treatment information related to the liver. More than 1,100
figures and tables, many new and in full color, highlight
completely updated content throughout. Expert, international
authorship and comprehensive, easy-to-access information makes this
edition the gold standard in the field of hepatology. Expert
ConsultT eBook version included with purchase. This enhanced eBook
experience allows you to search all of the text, figures, videos,
and references from the book on a variety of devices. Includes new
information on the rapid changes in treatment paradigms for acute
liver failure, the latest treatments for primary biliary
cholangitis, full coverage of the gut microbiome and its role in
liver disease, the newest developments in drug-induced liver
injury, and changes in hepatitis C virus treatment and hot-button
concerns about access to care. New summary boxes at the end of each
chapter and a newly streamlined table of contents make it easier to
find and understand the information you're looking for. Hundreds of
brand-new illustrations clearly present key aspects of liver
disease.
The condition of prolonged obstructive jaundice with patent bile
ducts was first described in 1851 by Addison and Gull of Guy's
Hospital, London. The term primary biliary cirrhosis (PBC) was
defined in 1950 by Ahrens and colleagues of the Rockefeller
Institute, New York. The condition was considered rare but this
changed in 1965 with the discovery of a definitive diagnostic serum
mitochondrial antibody test and the recognition that a raised serum
alkaline phosphatase value, often discovered incidentally, could be
a diagnostic pointer. If the diagnosis is made earlier, the end
stages are rarely reached as death is replaced by liver
transplantation. On November 6th 1997, in Chicago, an International
Faculty discussed in depth the clinical features, pathogenesis and
treatment of PBC, no longer considered a rare disease. The course
of PBC is long, but some 18 years after the discovery of a positive
mitochondrial antibody test in a symptom free patient with normal
serum biochemistry, 83% will have developed abnormal tests and 76%
will be symptomatic. Identification of those who will progress
rapidly is difficult. The serum antimitochondrial profile may be
useful but this is a very specialist technique. Mathematical
prognostic models are useful in therapeutic trials and in the
selection and timing of patients for liver transplantation but have
limited value in individual patients. An increasing serum bilirubin
level remains the most important indicator of rapid progression.
Its value however can be negated by the use of ursodeoxycholic acid
which has a bilirubin-lowering effect."
The condition of prolonged obstructive jaundice with patent bile
ducts was first described in 1851 by Addison and Gull of Guy's
Hospital, London. The term primary biliary cirrhosis (PBC) was
defined in 1950 by Ahrens and colleagues of the Rockefeller
Institute, New York. The condition was considered rare but this
changed in 1965 with the discovery of a definitive diagnostic serum
mitochondrial antibody test and the recognition that a raised serum
alkaline phosphatase value, often discovered incidentally, could be
a diagnostic pointer. If the diagnosis is made earlier, the end
stages are rarely reached as death is replaced by liver
transplantation. On November 6th 1997, in Chicago, an International
Faculty discussed in depth the clinical features, pathogenesis and
treatment of PBC, no longer considered a rare disease. The course
of PBC is long, but some 18 years after the discovery of a positive
mitochondrial antibody test in a symptom free patient with normal
serum biochemistry, 83% will have developed abnormal tests and 76%
will be symptomatic. Identification of those who will progress
rapidly is difficult. The serum antimitochondrial profile may be
useful but this is a very specialist technique. Mathematical
prognostic models are useful in therapeutic trials and in the
selection and timing of patients for liver transplantation but have
limited value in individual patients. An increasing serum bilirubin
level remains the most important indicator of rapid progression.
Its value however can be negated by the use of ursodeoxycholic acid
which has a bilirubin-lowering effect."
|
|